Bracco Imaging SpA. is buying prostate cancer imaging specialist Blue Earth Diagnostics Ltd. for $450 million, acquiring full rights to Axumin (F18-fluciclovine), a PET radiocontrast agent originally developed by Chicago-based GE Healthcare.

Japanese biopharma Carna Biosciences Inc. and Gilead Sciences Inc., of Foster City, Calif., have signed a $470 million R&D collaboration to develop and commercialize small-molecule compounds in immuno-oncology. Under the agreement, Gilead will license worldwide rights to develop and commercialize inhibitors against an undisclosed immuno-oncology target from Kobe, Japan-based Carna. Additionally, Gilead will have access to Carna's lipid kinase drug discovery platform.